OCON Therapeutics Secures $10M in Funding to Revolutionize Women’s Health with Advanced Drug Delivery Solutions
OCON Therapeutics has been awarded the 2024 Seal of Excellence from the EU Commission – recognizing top-tier innovative ideas worthy of investment – for its IUB® Platform’s innovative nature and potential to drive meaningful change for women and families in the EU and globally.
OCON Therapeutics contributed to the World Economic Forum and McKinsey Health Institute’s report, “Closing the Women’s Health Gap: A $1 Trillion Opportunity to Improve Lives and Economies.”
OCON Therapeutics has reached its recruitment goal of its Phase IIb clinical study evaluating the revolutionary IUB® SEAD®, a non-invasive treatment for heavy menstrual bleeding affecting 1 in 3 women
OCON Therapeutics is honored to be part of Bolt PR’s (A Millwright Agency) important list of Femtech Brands and Innovations to watch in 2023
OCON Therapeutics participating in the World Economic Forum’s Industry Strategy Meeting in Geneva as Technology Pioneer
OCON Therapeutics’s CEO, Keren Leshem, recognized as 1 in 10 Israeli women to watch in 2023
OCON Therapeutics’s CEO, Keren Leshem, recognized amongst 10 extraordinary female CEOs to watch in 2023
OCON Therapeutics speaking at the World Government Summit in Dubai on important Women’s Health issues
OCON Therapeutics’s CEO, Keren Leshem, named as 1 of 100 women of Influence by Entrepreneur Magazine
